Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
| Title: | Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant |
|---|---|
| Authors: | Slade, Michael J. 1, ⁎; Fortier, Julie 1; Khaled, Abir 2; Fiala, Mark 1; McDonald, Zac 2; Zaydman, Mark A. 3; Wan, Fei 4; Schroeder, Mark A. 1; Stockerl-Goldstein, Keith 1; Yang, Liqiang 2; Vij, Ravi 1 |
| Source: | In Clinical Lymphoma, Myeloma and Leukemia April 2025 |
| Database: | ScienceDirect |